U.S. Rare Disease Bio Executives Realize Billions in Stock Option Gains

United Therapeutics Corp. (NASDAQ: UTHR) CEO Martin A. Rothblatt exercised 9,500 stock options on both May 7 and May 11, immediately selling the same number of shares in the open market on each date. The shares traded in the high-$570 to low-$590 range, generating approximately $5.5 million to $5.7 million in proceeds per transaction—equivalent to an estimated gain of around KRW 70 billion. Following these sales, Rothblatt still holds roughly 40,000 shares directly and maintains indirect holdings of several hundred thousand shares through his spouse and a family trust. The option exercises and share sales were conducted under a Rule 10b5-1 trading plan established on November 7, 2025.

On the same day, Chief Financial Officer James Edgemond exercised 10,000 stock options and sold all 10,000 shares at around $570 per share, generating proceeds of approximately $5.75 million to $5.8 million (about KRW 70 billion). After the transaction, Edgemond retains roughly 18,000 shares. His trades, too, were executed under a Rule 10b5-1 plan, which he put in place on October 31, 2025, and carried out across multiple price levels.

In its May 6 release of first-quarter 2026 results, United Therapeutics reported earnings per share below market expectations but continued to operate on the strength of its existing product portfolio, including treatments for pulmonary arterial hypertension. In May, the company also received FDA approval to initiate the first human clinical trial of UHeart, its gene-edited pig heart. Additionally, United Therapeutics is collaborating with aerospace startup Varda Space Industries to explore chronic-disease drug candidates in the space environment, underscoring its commitment to pipeline expansion.

United Therapeutics Corporation is a Nasdaq-listed U.S. biotechnology company organized as a public benefit corporation. It develops therapies for rare and serious pulmonary diseases—such as pulmonary arterial hypertension—while advancing xenotransplantation research using gene-edited pig organs. Alongside its flagship treprostinil-class PAH treatments, the company is positioning its regenerative and xenotransplant platforms for heart and lung replacement as key long-term growth drivers.